Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-04-07

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In 2005, around 30,000 renal transplants were conducted in the seven major markets. In order to prevent the patient's immune system from rejecting the transplanted organ, daily immunosuppression therapy is a necessity for the lifetime of the graft with a base maintenance drug (cyclosporine, tacrolimus, sirolimus) combined with adjunctive therapies (azathioprine, mycophenolate mofetil, steroids).


Scope

  • Historical and recent trends in immunosuppressive therapy including current clinical practice and clinical advantages and side effects of treatments
  • Organ supply, national donation rates, waiting lists and forecasts of the number of transplants and maintenance populations to 2015
  • Primary diagnosis, graft survival rates, reasons for late graft failure and risk factors associated with acute rejection
  • Future market outlook including calcineurin inhibitor avoidance/withdrawal strategies


    • Report Highlights
    30,000 renal transplants were performed in 2005, increasing to 43,000 by 2015 (CAGR, 2005-15, 4%), although the organ gap may widen further as increasing morbidity, such as diabetes mellitus, drives demand.

    The number of patients with functioning kidney transplants will double to 428,000 by 2015, creating a large group of patients with unique and complex long-term medical care needs directly attributable to adverse effects of immunosuppressive drugs, including nephrotoxicity, diabetes, hypertension, hyperlipidemia and vulnerability to infection.

    Although prevention of acute rejection remains a primary treatment goal, agents that do not impair long-term renal function are required. While results from sirolimus based calcineurin-inhibitor withdrawal regimens are inconclusive more promising results are emerging from use in the calcineurin-inhibitor avoidance or switching setting.


    Reasons to Purchase

  • Identify changing trends in immunosuppressive protocols
  • Understand the most common treatment protocols in renal transplantation by patient type
  • Quantify the future market size based on the number of transplants and renal maintenance populations

    • Table of Contents

    Other users found this report page using the following search terms: tranplantation organ transplant transplant immunosuppression market kidney renal post transplantation immunosuppressants size history

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.